Advertisement
Australia markets close in 5 hours 33 minutes
  • ALL ORDS

    8,083.70
    +18.20 (+0.23%)
     
  • ASX 200

    7,814.00
    +20.70 (+0.27%)
     
  • AUD/USD

    0.6593
    -0.0008 (-0.12%)
     
  • OIL

    78.24
    -0.14 (-0.18%)
     
  • GOLD

    2,323.20
    -1.00 (-0.04%)
     
  • Bitcoin AUD

    95,054.63
    -1,181.27 (-1.23%)
     
  • CMC Crypto 200

    1,296.15
    -68.98 (-5.05%)
     
  • AUD/EUR

    0.6130
    -0.0001 (-0.02%)
     
  • AUD/NZD

    1.0984
    -0.0003 (-0.03%)
     
  • NZX 50

    11,787.21
    -13.57 (-0.11%)
     
  • NASDAQ

    18,091.45
    -2.12 (-0.01%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • Dow Jones

    38,884.26
    +31.99 (+0.08%)
     
  • DAX

    18,430.05
    +254.84 (+1.40%)
     
  • Hang Seng

    18,479.37
    -98.93 (-0.53%)
     
  • NIKKEI 225

    38,560.33
    -274.77 (-0.71%)
     

As Solvar (ASX:SVR) soars 12% this past week, investors may now be noticing the company's three-year earnings growth

It's nice to see the Solvar Limited (ASX:SVR) share price up 12% in a week. But that doesn't change the fact that the returns over the last three years have been disappointing. Regrettably, the share price slid 62% in that period. Some might say the recent bounce is to be expected after such a bad drop. Perhaps the company has turned over a new leaf.

Although the past week has been more reassuring for shareholders, they're still in the red over the last three years, so let's see if the underlying business has been responsible for the decline.

Check out our latest analysis for Solvar

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

ADVERTISEMENT

During the unfortunate three years of share price decline, Solvar actually saw its earnings per share (EPS) improve by 5.6% per year. This is quite a puzzle, and suggests there might be something temporarily buoying the share price. Or else the company was over-hyped in the past, and so its growth has disappointed.

Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.

Given the healthiness of the dividend payments, we doubt that they've concerned the market. We like that Solvar has actually grown its revenue over the last three years. If the company can keep growing revenue, there may be an opportunity for investors. You might have to dig deeper to understand the recent share price weakness.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. This free report showing analyst forecasts should help you form a view on Solvar

What About Dividends?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, Solvar's TSR for the last 3 years was -53%, which exceeds the share price return mentioned earlier. And there's no prize for guessing that the dividend payments largely explain the divergence!

A Different Perspective

Investors in Solvar had a tough year, with a total loss of 28% (including dividends), against a market gain of about 17%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 5% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 4 warning signs for Solvar (1 can't be ignored) that you should be aware of.

Solvar is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.